SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001664710-24-000039
Filing Date
2024-05-08
Accepted
2024-05-08 08:03:42
Documents
51
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q kros-20240331.htm   iXBRL 10-Q 982637
2 EX-31.1 exhibit311q12024.htm EX-31.1 17230
3 EX-31.2 exhibit312q12024.htm EX-31.2 17111
4 EX-32.1 exhibit321q12024.htm EX-32.1 9843
  Complete submission text file 0001664710-24-000039.txt   3791692

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kros-20240331.xsd EX-101.SCH 24235
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT kros-20240331_cal.xml EX-101.CAL 39725
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT kros-20240331_def.xml EX-101.DEF 96363
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kros-20240331_lab.xml EX-101.LAB 378598
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kros-20240331_pre.xml EX-101.PRE 247111
54 EXTRACTED XBRL INSTANCE DOCUMENT kros-20240331_htm.xml XML 252488
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

IRS No.: 811173868 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39264 | Film No.: 24924317
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)